BI Asset Management Fondsmaeglerselskab’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.25M | Buy |
6,912
+1,570
| +29% | +$512K | 0.02% | 343 |
|
|
2025
Q1 | $1.44M | Sell |
5,342
-6,413
| -55% | -$1.73M | 0.02% | 369 |
|
|
2024
Q4 | $2.77M | Buy |
11,755
+3,232
| +38% | +$761K | 0.03% | 299 |
|
|
2024
Q3 | $2.34M | Buy |
8,523
+3,961
| +87% | +$1.09M | 0.04% | 260 |
|
|
2024
Q2 | $1.11M | Buy |
4,562
+838
| +23% | +$204K | 0.02% | 378 |
|
|
2024
Q1 | $557K | Sell |
3,724
-45
| -1% | -$6.73K | 0.01% | 504 |
|
|
2023
Q4 | $721K | Buy |
3,769
+2,076
| +123% | +$397K | 0.02% | 459 |
|
|
2023
Q3 | $300K | Sell |
1,693
-516
| -23% | -$91.4K | 0.01% | 565 |
|
|
2023
Q2 | $420K | Sell |
2,209
-9,853
| -82% | -$1.87M | 0.01% | 516 |
|
|
2023
Q1 | $2.42M | Buy |
12,062
+6,432
| +114% | +$1.29M | 0.06% | 206 |
|
|
2022
Q4 | $1.34M | Buy |
5,630
+2,721
| +94% | +$647K | 0.04% | 280 |
|
|
2022
Q3 | $582K | Sell |
2,909
-221
| -7% | -$44.2K | 0.03% | 263 |
|
|
2022
Q2 | $457K | Buy |
3,130
+1,262
| +68% | +$184K | 0.02% | 330 |
|
|
2022
Q1 | $305K | Buy |
+1,868
| New | +$305K | 0.01% | 353 |
|
|
2020
Q4 | – | Sell |
-293
| Closed | -$43K | – | 380 |
|
|
2020
Q3 | $43K | Buy |
+293
| New | +$43K | ﹤0.01% | 444 |
|